We analyzed associations of polymorphic markers of DNA repair genes ( XRCC1 , ERCC2 ), cell cycle control genes ( TP53 , MDM2 , and CDKN1A ), methylation of promoter region, and mutation 5382insC of BRCA1 gene in ovarian cancer with effectiveness of platinumbased chemotherapy assessed by the median of progression-free survival time for markers of DNA repair genes and by relapse risk for all studied markers. An increase in the median of progression-free survival time for carriers of the Gln allele ( р =0.025) and Gln / Gln genotype ( р =0.022) of the Gln399Arg XRCC1 was observed during the 19-months period after chemotherapy. In carriers of C / C genotype of 5382insC mutation of BRCA1 gene ( n =6), no relapses were observed ( р =0.035), while 17 of 49 patients without this mutation developed relapses. Of 14 patients with BRCA1 gene function inactivation due to promoter methylation or the presence of the C / C genotype of 5382insC , one relapse was observed ( p =0.033). Multivariate analysis revealed an association of markers of the XRCC1 , TP53 , MDM2 genes, BRCA1 gene inactivation, and type of surgery with the risk of relapse during the follow-up period up to 19 months after the end of chemotherapy ( р ≤0.0007).